Trastuzumab emtansine for HER2-positive advanced breast cancer

Sunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark Pegram, Do Youn Oh, Véronique Diéras, Ellie Guardino, Liang Fang, Michael W. Lu, Steven Olsen, Kim Blackwell

Research output: Contribution to journalArticle

1640 Citations (Scopus)

Abstract

BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are conjugated by means of a stable linker. METHODS: We randomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine. The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety. Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression. Two interim analyses of overall survival were conducted. RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 months with T-DM1 versus 6.4 months with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P

Original languageEnglish
Pages (from-to)1783-1791
Number of pages9
JournalNew England Journal of Medicine
Volume367
Issue number19
DOIs
Publication statusPublished - Nov 8 2012

Fingerprint

Disease-Free Survival
Breast Neoplasms
Antibodies
Cytotoxins
Survival Analysis
Microtubules
Cause of Death
Research Personnel
Confidence Intervals
Safety
Survival
Pharmaceutical Preparations
human ERBB2 protein
ado-trastuzumab emtansine
lapatinib
Capecitabine
Trastuzumab
taxane

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., ... Blackwell, K. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367(19), 1783-1791. https://doi.org/10.1056/NEJMoa1209124

Trastuzumab emtansine for HER2-positive advanced breast cancer. / Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, José; Pegram, Mark; Oh, Do Youn; Diéras, Véronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim.

In: New England Journal of Medicine, Vol. 367, No. 19, 08.11.2012, p. 1783-1791.

Research output: Contribution to journalArticle

Verma, S, Miles, D, Gianni, L, Krop, IE, Welslau, M, Baselga, J, Pegram, M, Oh, DY, Diéras, V, Guardino, E, Fang, L, Lu, MW, Olsen, S & Blackwell, K 2012, 'Trastuzumab emtansine for HER2-positive advanced breast cancer', New England Journal of Medicine, vol. 367, no. 19, pp. 1783-1791. https://doi.org/10.1056/NEJMoa1209124
Verma, Sunil ; Miles, David ; Gianni, Luca ; Krop, Ian E. ; Welslau, Manfred ; Baselga, José ; Pegram, Mark ; Oh, Do Youn ; Diéras, Véronique ; Guardino, Ellie ; Fang, Liang ; Lu, Michael W. ; Olsen, Steven ; Blackwell, Kim. / Trastuzumab emtansine for HER2-positive advanced breast cancer. In: New England Journal of Medicine. 2012 ; Vol. 367, No. 19. pp. 1783-1791.
@article{79a2c759983a455e9caa199f138d666a,
title = "Trastuzumab emtansine for HER2-positive advanced breast cancer",
abstract = "BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are conjugated by means of a stable linker. METHODS: We randomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine. The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety. Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression. Two interim analyses of overall survival were conducted. RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 months with T-DM1 versus 6.4 months with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95{\%} confidence interval [CI], 0.55 to 0.77; P",
author = "Sunil Verma and David Miles and Luca Gianni and Krop, {Ian E.} and Manfred Welslau and Jos{\'e} Baselga and Mark Pegram and Oh, {Do Youn} and V{\'e}ronique Di{\'e}ras and Ellie Guardino and Liang Fang and Lu, {Michael W.} and Steven Olsen and Kim Blackwell",
year = "2012",
month = "11",
day = "8",
doi = "10.1056/NEJMoa1209124",
language = "English",
volume = "367",
pages = "1783--1791",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "19",

}

TY - JOUR

T1 - Trastuzumab emtansine for HER2-positive advanced breast cancer

AU - Verma, Sunil

AU - Miles, David

AU - Gianni, Luca

AU - Krop, Ian E.

AU - Welslau, Manfred

AU - Baselga, José

AU - Pegram, Mark

AU - Oh, Do Youn

AU - Diéras, Véronique

AU - Guardino, Ellie

AU - Fang, Liang

AU - Lu, Michael W.

AU - Olsen, Steven

AU - Blackwell, Kim

PY - 2012/11/8

Y1 - 2012/11/8

N2 - BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are conjugated by means of a stable linker. METHODS: We randomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine. The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety. Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression. Two interim analyses of overall survival were conducted. RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 months with T-DM1 versus 6.4 months with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P

AB - BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are conjugated by means of a stable linker. METHODS: We randomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine. The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety. Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression. Two interim analyses of overall survival were conducted. RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 months with T-DM1 versus 6.4 months with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P

UR - http://www.scopus.com/inward/record.url?scp=84868520609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868520609&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1209124

DO - 10.1056/NEJMoa1209124

M3 - Article

VL - 367

SP - 1783

EP - 1791

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 19

ER -